Palisade Bio's Lead Product Candidate, PALI-2108 Demonstrates Local Bioactivation and Dose Dependent Efficacy Response in Preclinical Mouse Models

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Carlsbad, CA, May 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today ann ...